Ankara University

ankara.edu.tr

Total trials

300

Active

64

Phase 3

2

Total enrollment

54,647

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Lu-177 PSMA-6171
Terbium 161- PSMA I&T1
bioceramic based intracanal medication1
Calcium Hydroxide Intracanal medication1
Chemotherapy1
Preemptive Multimodal Intravenous Analgesia1
İNTRATECHAL MORPHİNE GROUP1

Next readouts

  • 2024-11-30
  • 2025-05-30
  • 2025-11-25
  • 2026-04-15
  • 2028-02-01
  • 2028-08-01

Top conditions

  • Stroke7
  • Pain6
  • Postoperative Pain6
  • Anxiety5
  • Parkinson Disease5
  • Acute Kidney Injury5
  • Anesthesia5
  • Pain, Postoperative4

Frequently asked questions about Ankara University

How many clinical trials does Ankara University have on ClinicalTrials.gov?
Ankara University is listed as the lead sponsor on 300 clinical trials in ClinicalTrials.gov, 64 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ankara University's trials are in Phase 3?
2 of Ankara University's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Ankara University focus on?
Ankara University's most-studied conditions on ClinicalTrials.gov are Stroke, Pain, Postoperative Pain, Anxiety, Parkinson Disease.
When are Ankara University's next clinical trial readouts?
Ankara University has 6 upcoming primary-completion readouts tracked here; the soonest is “The Effect of Intrathecal Morphine and Erector Spina Plan Block on Serum Cytokine Levels and Chronic Pain in Caesarean Section Surgery”, expected around 2024-11-30.